Vitamin K epoxide reductases : Questions médicales fréquentes
Nom anglais: Vitamin K Epoxide Reductases
Descriptor UI:D064417
Tree Number:D08.811.682.690.708.961
Termes MeSH sélectionnés :
Programmed Cell Death 1 Receptor
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Vitamin K epoxide reductases : Questions médicales les plus fréquentes",
"headline": "Vitamin K epoxide reductases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Vitamin K epoxide reductases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-10",
"dateModified": "2025-05-05",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Vitamin K epoxide reductases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Mixed function oxygenases",
"url": "https://questionsmedicales.fr/mesh/D006899",
"about": {
"@type": "MedicalCondition",
"name": "Mixed function oxygenases",
"code": {
"@type": "MedicalCode",
"code": "D006899",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.690.708"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Vitamin K epoxide reductases",
"alternateName": "Vitamin K Epoxide Reductases",
"code": {
"@type": "MedicalCode",
"code": "D064417",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Virginie Lattard",
"url": "https://questionsmedicales.fr/author/Virginie%20Lattard",
"affiliation": {
"@type": "Organization",
"name": "USC 1233 RS2GP, INRA, VetAgro Sup, Univ Lyon, F-69280 Marcy l'Etoile, France."
}
},
{
"@type": "Person",
"name": "Maria Fusaro",
"url": "https://questionsmedicales.fr/author/Maria%20Fusaro",
"affiliation": {
"@type": "Organization",
"name": "National Research Council (CNR), Institute of Clinical Physiology (IFC), 56124 Pisa, Italy."
}
},
{
"@type": "Person",
"name": "Nolan Chatron",
"url": "https://questionsmedicales.fr/author/Nolan%20Chatron",
"affiliation": {
"@type": "Organization",
"name": "USC 1233 RS2GP, INRA, VetAgro Sup, Univ Lyon, F-69280 Marcy l'Etoile, France."
}
},
{
"@type": "Person",
"name": "Luba Tchertanov",
"url": "https://questionsmedicales.fr/author/Luba%20Tchertanov",
"affiliation": {
"@type": "Organization",
"name": "Centre Borelli, ENS Paris-Saclay, CNRS, Université Paris-Saclay, 4 Avenue Des Sciences, F-91190 Gif-sur-Yvette, France."
}
},
{
"@type": "Person",
"name": "Weikai Li",
"url": "https://questionsmedicales.fr/author/Weikai%20Li",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO 63110, USA. Electronic address: weikai@wustl.edu."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Programmed cell death-1 blockade therapy in melanoma: Resistance mechanisms and combination strategies.",
"datePublished": "2023-01-24",
"url": "https://questionsmedicales.fr/article/36645031",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/exd.14750"
}
},
{
"@type": "ScholarlyArticle",
"name": "MicroRNAs Targeting Programmed Cell Death Protein 1 (PD-1) Promote Natural Killer Cell Exhaustion in Rheumatoid Arthritis.",
"datePublished": "2022-12-24",
"url": "https://questionsmedicales.fr/article/36640056",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.18502/ijaai.v21i6.11524"
}
},
{
"@type": "ScholarlyArticle",
"name": "Differential expression of programmed death 1 (PD-1) on various immune cells and its role in human leprosy.",
"datePublished": "2023-04-21",
"url": "https://questionsmedicales.fr/article/37153623",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2023.1138145"
}
},
{
"@type": "ScholarlyArticle",
"name": "A High Programmed Cell Death Protein 1 Hormone Receptor Score on Skin Biopsy is Associated with Sézary Syndrome Diagnosis: A Study of 91 Patients with Erythroderma.",
"datePublished": "2022-09-06",
"url": "https://questionsmedicales.fr/article/35758515",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2340/actadv.v102.1062"
}
},
{
"@type": "ScholarlyArticle",
"name": "Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.",
"datePublished": "2022-11-25",
"url": "https://questionsmedicales.fr/article/36442821",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.actbio.2022.11.043"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Oxidoreductases",
"item": "https://questionsmedicales.fr/mesh/D010088"
},
{
"@type": "ListItem",
"position": 5,
"name": "Oxygénases",
"item": "https://questionsmedicales.fr/mesh/D010105"
},
{
"@type": "ListItem",
"position": 6,
"name": "Mixed function oxygenases",
"item": "https://questionsmedicales.fr/mesh/D006899"
},
{
"@type": "ListItem",
"position": 7,
"name": "Vitamin K epoxide reductases",
"item": "https://questionsmedicales.fr/mesh/D064417"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Vitamin K epoxide reductases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Vitamin K epoxide reductases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-15",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Vitamin K epoxide reductases",
"description": "Comment diagnostiquer une carence en vitamine K ?\nQuels tests sont utilisés pour évaluer l'activité des réductases ?\nQuels symptômes indiquent un dysfonctionnement des réductases ?\nComment les médicaments affectent-ils le diagnostic ?\nQuel rôle joue l'alimentation dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D064417?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Vitamin K epoxide reductases",
"description": "Quels sont les symptômes d'une carence en vitamine K ?\nComment se manifestent les troubles de coagulation ?\nLes douleurs articulaires sont-elles liées aux réductases ?\nQuels signes cutanés peuvent apparaître ?\nLes saignements menstruels peuvent-ils être affectés ?",
"url": "https://questionsmedicales.fr/mesh/D064417?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Vitamin K epoxide reductases",
"description": "Comment prévenir une carence en vitamine K ?\nLes suppléments sont-ils recommandés ?\nQuels aliments sont riches en vitamine K ?\nLes personnes âgées ont-elles besoin de plus de vitamine K ?\nComment éviter les interactions médicamenteuses ?",
"url": "https://questionsmedicales.fr/mesh/D064417?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Vitamin K epoxide reductases",
"description": "Comment traiter une carence en vitamine K ?\nQuels médicaments peuvent interférer avec les réductases ?\nY a-t-il des traitements alternatifs ?\nComment surveiller l'efficacité du traitement ?\nLes transfusions sanguines sont-elles nécessaires ?",
"url": "https://questionsmedicales.fr/mesh/D064417?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Vitamin K epoxide reductases",
"description": "Quelles complications peuvent survenir en cas de carence ?\nLes complications sont-elles réversibles ?\nQuels risques sont associés à un surdosage de vitamine K ?\nLes complications affectent-elles la grossesse ?\nComment les maladies hépatiques influencent-elles les complications ?",
"url": "https://questionsmedicales.fr/mesh/D064417?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Vitamin K epoxide reductases",
"description": "Quels sont les facteurs de risque de carence en vitamine K ?\nLes nouveau-nés sont-ils à risque ?\nLes personnes sous anticoagulants sont-elles à risque ?\nLes maladies intestinales augmentent-elles le risque ?\nLes personnes âgées sont-elles plus vulnérables ?",
"url": "https://questionsmedicales.fr/mesh/D064417?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une carence en vitamine K ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un dosage des niveaux de prothrombine et de vitamine K dans le sang peut indiquer une carence."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité des réductases ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de coagulation comme le temps de prothrombine (TP) sont utilisés pour évaluer l'activité."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un dysfonctionnement des réductases ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des saignements excessifs ou des ecchymoses fréquentes peuvent indiquer un dysfonctionnement."
}
},
{
"@type": "Question",
"name": "Comment les médicaments affectent-ils le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains anticoagulants, comme la warfarine, peuvent fausser les résultats des tests de coagulation."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'alimentation dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation pauvre en vitamine K peut contribuer à des résultats anormaux lors des tests."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une carence en vitamine K ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des saignements, des ecchymoses, et des saignements des gencives."
}
},
{
"@type": "Question",
"name": "Comment se manifestent les troubles de coagulation ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils se manifestent par des saignements prolongés après une blessure ou des hémorragies internes."
}
},
{
"@type": "Question",
"name": "Les douleurs articulaires sont-elles liées aux réductases ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs articulaires peuvent survenir en raison de saignements internes dans les articulations."
}
},
{
"@type": "Question",
"name": "Quels signes cutanés peuvent apparaître ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des ecchymoses et des éruptions cutanées peuvent apparaître en cas de carence en vitamine K."
}
},
{
"@type": "Question",
"name": "Les saignements menstruels peuvent-ils être affectés ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des saignements menstruels plus abondants peuvent être un signe de carence en vitamine K."
}
},
{
"@type": "Question",
"name": "Comment prévenir une carence en vitamine K ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée riche en légumes à feuilles vertes aide à prévenir la carence."
}
},
{
"@type": "Question",
"name": "Les suppléments sont-ils recommandés ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des suppléments peuvent être recommandés pour les personnes à risque, comme les nouveau-nés."
}
},
{
"@type": "Question",
"name": "Quels aliments sont riches en vitamine K ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les légumes à feuilles vertes, le brocoli et les huiles végétales sont riches en vitamine K."
}
},
{
"@type": "Question",
"name": "Les personnes âgées ont-elles besoin de plus de vitamine K ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées peuvent nécessiter un apport accru en raison de l'absorption réduite."
}
},
{
"@type": "Question",
"name": "Comment éviter les interactions médicamenteuses ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est important de consulter un médecin avant de prendre des suppléments ou des médicaments."
}
},
{
"@type": "Question",
"name": "Comment traiter une carence en vitamine K ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement inclut des suppléments de vitamine K par voie orale ou intraveineuse."
}
},
{
"@type": "Question",
"name": "Quels médicaments peuvent interférer avec les réductases ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les anticoagulants comme la warfarine peuvent inhiber l'activité des réductases."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements alternatifs ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des modifications alimentaires pour augmenter l'apport en vitamine K peuvent être bénéfiques."
}
},
{
"@type": "Question",
"name": "Comment surveiller l'efficacité du traitement ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de coagulation réguliers permettent de surveiller l'efficacité du traitement."
}
},
{
"@type": "Question",
"name": "Les transfusions sanguines sont-elles nécessaires ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Dans les cas graves, des transfusions de plasma peuvent être nécessaires pour traiter les saignements."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir en cas de carence ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des hémorragies graves et des troubles de la coagulation."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, avec un traitement approprié, la plupart des complications peuvent être réversibles."
}
},
{
"@type": "Question",
"name": "Quels risques sont associés à un surdosage de vitamine K ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un surdosage peut entraîner des problèmes de coagulation et des réactions allergiques."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la grossesse ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une carence en vitamine K peut augmenter le risque de complications pendant la grossesse."
}
},
{
"@type": "Question",
"name": "Comment les maladies hépatiques influencent-elles les complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les maladies hépatiques peuvent altérer le métabolisme de la vitamine K, augmentant les risques de complications."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque de carence en vitamine K ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent une alimentation déséquilibrée, des troubles d'absorption et certains médicaments."
}
},
{
"@type": "Question",
"name": "Les nouveau-nés sont-ils à risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les nouveau-nés ont un risque accru de carence en raison de réserves limitées de vitamine K."
}
},
{
"@type": "Question",
"name": "Les personnes sous anticoagulants sont-elles à risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes sous anticoagulants comme la warfarine doivent surveiller leur apport en vitamine K."
}
},
{
"@type": "Question",
"name": "Les maladies intestinales augmentent-elles le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les maladies comme la maladie cœliaque peuvent affecter l'absorption de la vitamine K."
}
},
{
"@type": "Question",
"name": "Les personnes âgées sont-elles plus vulnérables ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'absorption de la vitamine K peut diminuer avec l'âge, augmentant le risque de carence."
}
}
]
}
]
}
Melanoma is a highly aggressive tumor derived from melanocytes. In recent years, the incidence and mortality of melanoma have gradually increased, seriously threatening human health. Classic treatment...
Natural killer (NK) cells play a role in the pathogenesis of rheumatoid arthritis (RA). Upregulated levels of programmed cell death protein 1 (PD-1) is a sign of exhausted NK cells that could be regul...
Erythroderma is challenging to diagnose. The aim of this single-centre retrospective study was to identify factors that can be used to improve the diagnosis of erythroderma. Among 91 patients with ery...
Immune checkpoint blockade therapy targeting programmed death-1 (PD-1) or its major ligand programmed death-ligand 1 (PD-L1) has achieved remarkable success in the treatment of several tumors, includi...
The immune system uses various immune checkpoint axes to adjust responses, support homeostasis, and deter self-reactivity and autoimmunity. Nevertheless, non-small-cell lung carcinoma (NSCLC) can use ...
Pembrolizumab or nivolumab plus chemotherapy was approved as a first-line treatment for high programmed cell death ligand 1 (PD-L1)-expressing esophageal squamous cell carcinoma (ESCC) by the European...
Post hoc analysis of the Chinese JUPITER-06 study focusing on efficacy stratified by PD-L1 tumor proportion score (TPS; using JS311 antibody) was conducted. Electronic databases were searched to ident...
The post hoc analysis of JUPITER-06 showed more prominent clinical benefit with PD-1 antibody plus chemotherapy than with chemotherapy alone in both the high and low PD-L1-expressing subgroups. Five r...
This study provided novel evidence supporting the superiority of PD-1 antibody plus chemotherapy to chemotherapy alone in patients with advanced ESCC with low PD-L1 expression. Further studies of pred...
Major depression (MD) may be associated with inflammation and immunity. PD-1 (programmed death-1), PD-L1 (programmed death-ligand 1) and PD-L2 (programmed death-ligand 2) are among the inhibitory immu...
During a period of 2 years, patients with MD and healthy controls were recruited from a medical centre in this study. The diagnosis of MD was established according to the DSM-5 criteria. The severity ...
A total of 54 patients with MD and 38 healthy controls were recruited. According to the analyses, there is a significantly higher PD-L2 level in MD than in healthy controls and lower PD-1 level after ...
It was found that PD-1 pathway might play an important role in MD. We need a large sample to prove these results in the future....
Tumor-infiltrating lymphocytes are detectable in up to 75% of triple-negative breast cancer. The composition of these infiltrates may influence prognosis and is not known regarding regulatory or effec...
This was a retrospective observational study. Clinical and pathological data from 38 triple-negative breast cancer patients treated with neoadjuvant chemotherapy at the University Hospital (HUCFF/UFRJ...
Statistically significant changes in stromal tumor-infiltrating lymphocyte categories were observed before and post-neoadjuvant chemotherapy, with 32% of intermediate cases becoming high. The correlat...
In this study, we observed that chemotherapy significantly increases stromal tumor-infiltrating lymphocytes, CD8 T cells, as well as CD8/FoxP3 ratio. Most importantly, programmed cell death protein 1 ...
Melanoma is widely treated with programmed cell death-1 (PD-1) inhibitors. As part of their anti-tumor immunity effect, they increase the susceptibility to cutaneous immune-related adverse events (cIR...